Compare Global X Artificial Intelligence & Technology ETF (AIQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Artificial Intelligence & Technology ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.75, while Vertex Pharmaceuticals Incorporated trades at $527.48 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | VRTX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $529.65 |
52-Week Low | $43.88 | $376.62 |
Market Cap | — | $134.25B |
Enterprise Value | — | $128.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIQ trades at $63.69, up 0.28% today, with a bullish technical signal from moving averages and a neutral stance from oscillators. The stock recently crossed above its 200-day moving average of $56.52, indicating positive momentum. Recent news highlights AIQ's outperformance versus the Nasdaq and its role in the AI investment theme, though financial ratios are not provided in the snapshot.
The outlook for AIQ is tied to the AI sector's growth, with potential from thematic exposure and rebalancing strategies. Risks include high fees, sector volatility, and dependence on AI adoption trends. Analyst sentiment is mixed, with some praising diversification benefits while others note valuation concerns amid rapid gains.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Artificial Intelligence & Technology ETF
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
